CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Vitrolife - VITR CFD

    191.0
    0.21%
    3.2
    Low: 186.8
    High: 194.6
    Market Trading Hours* (UTC) Opens on Monday at 08:00

    Mon - Fri: 08:00 - 16:25

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Ownership
    Trading Conditions
    Spread 3.2
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.021947 %
    Charges from full value of position ($-4.17)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.021947%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.000275 %
    Charges from full value of position ($-0.05)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.000275%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency SEK
    Margin 5%
    Stock exchange Sweden
    Commission on trade 0%

    *Information provided by Capital.com

    Key Stats
    Prev. Close* 191.4
    Open* 192
    1-Year Change* 2.45%
    Day's Range* 186.8 - 194.6
    52 wk Range 123.90-269.60
    Average Volume (10 days) 122.18K
    Average Volume (3 months) 3.90M
    Market Cap 24.65B
    P/E Ratio 61.30
    Shares Outstanding 135.45M
    Revenue 3.46B
    EPS 2.97
    Dividend (Yield %) 0.46703
    Beta 1.84
    Next Earnings Date Feb 2, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 8, 2023 191.0 -1.0 -0.52% 192.0 195.4 185.4
    Dec 7, 2023 191.4 3.0 1.59% 188.4 192.0 181.8
    Dec 6, 2023 190.0 2.4 1.28% 187.6 191.8 182.8
    Dec 5, 2023 186.8 8.4 4.71% 178.4 187.6 176.8
    Dec 4, 2023 180.2 -0.8 -0.44% 181.0 182.2 176.0
    Dec 1, 2023 181.0 1.2 0.67% 179.8 182.2 176.2
    Nov 30, 2023 178.8 1.6 0.90% 177.2 179.8 172.8
    Nov 29, 2023 180.2 8.0 4.65% 172.2 180.6 170.8
    Nov 28, 2023 169.8 3.0 1.80% 166.8 171.8 164.6
    Nov 27, 2023 168.4 -0.8 -0.47% 169.2 171.2 165.6
    Nov 24, 2023 171.6 -8.0 -4.45% 179.6 181.2 170.2
    Nov 23, 2023 180.8 1.2 0.67% 179.6 182.8 178.0
    Nov 22, 2023 181.0 9.2 5.36% 171.8 181.0 171.8
    Nov 21, 2023 174.6 -1.2 -0.68% 175.8 176.8 172.0
    Nov 20, 2023 176.4 5.6 3.28% 170.8 177.0 169.2
    Nov 17, 2023 171.4 9.6 5.93% 161.8 172.2 161.8
    Nov 16, 2023 164.8 1.0 0.61% 163.8 166.2 160.0
    Nov 15, 2023 164.0 0.2 0.12% 163.8 173.0 163.2
    Nov 14, 2023 166.2 12.4 8.06% 153.8 166.4 152.0
    Nov 13, 2023 153.0 -4.0 -2.55% 157.0 157.6 151.6

    Vitrolife Events

    Time (UTC) Country Event
    Tuesday, December 12, 2023

    Time (UTC)

    09:00

    Country

    SE

    Event

    Vitrolife AB Capital Markets Day
    Vitrolife AB Capital Markets Day

    Forecast

    -

    Previous

    -
    Friday, February 2, 2024

    Time (UTC)

    07:30

    Country

    SE

    Event

    Q4 2023 Vitrolife AB Earnings Release
    Q4 2023 Vitrolife AB Earnings Release

    Forecast

    -

    Previous

    -

    Time (UTC)

    09:00

    Country

    SE

    Event

    Q4 2023 Vitrolife AB Earnings Call
    Q4 2023 Vitrolife AB Earnings Call

    Forecast

    -

    Previous

    -
    Thursday, April 18, 2024

    Time (UTC)

    06:00

    Country

    SE

    Event

    Q1 2024 Vitrolife AB Earnings Release
    Q1 2024 Vitrolife AB Earnings Release

    Forecast

    -

    Previous

    -

    Time (UTC)

    08:00

    Country

    SE

    Event

    Q1 2024 Vitrolife AB Earnings Call
    Q1 2024 Vitrolife AB Earnings Call

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 3234 1680.8 1245.57 1480.13 1151.35
    Revenue 3234 1680.8 1245.57 1480.13 1151.35
    Cost of Revenue, Total 1454 634.714 477.905 541.48 390.224
    Gross Profit 1780 1046.09 767.667 938.652 761.124
    Total Operating Expense 2602 1245.43 875.557 992.186 757.433
    Selling/General/Admin. Expenses, Total 787 467.794 293.688 335.715 279.775
    Research & Development 132 112.447 88.092 93.575 70.542
    Depreciation / Amortization 226 37.95 21.33 21.189 5.15
    Interest Expense (Income) - Net Operating -3 -8.309 5.744 0.037 3.963
    Unusual Expense (Income) 23 -1.342 -8.65 0.276 16.285
    Other Operating Expenses, Total -17 2.171 -2.552 -0.086 -8.506
    Operating Income 632 435.379 370.015 487.946 393.915
    Interest Income (Expense), Net Non-Operating -79 24.937 -3.832 4.702 4.692
    Other, Net -16 -0.347 0.008 0.046 -0.024
    Net Income Before Taxes 537 459.969 366.191 492.694 398.583
    Net Income After Taxes 394 343.564 287.866 383.839 310.697
    Minority Interest 0 -2.591 -1.02 -1.054 -1
    Net Income Before Extra. Items 394 340.973 286.846 382.785 309.697
    Net Income 394 340.973 286.846 382.785 309.697
    Income Available to Common Excl. Extra. Items 394 340.973 286.845 382.785 309.697
    Income Available to Common Incl. Extra. Items 394 340.973 286.845 382.785 309.697
    Diluted Net Income 394 340.973 286.845 382.785 309.697
    Diluted Weighted Average Shares 135.395 114.625 108.551 108.551 108.551
    Diluted EPS Excluding Extraordinary Items 2.91001 2.97468 2.6425 3.52633 2.85302
    Dividends per Share - Common Stock Primary Issue 0.85 0.8 0.8 0 0.85
    Diluted Normalized EPS 3.03465 3.62408 2.57986 3.52831 2.96996
    Total Adjustments to Net Income 0 -0.001
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 905 854 855 798 829
    Revenue 905 854 855 798 829
    Cost of Revenue, Total 400 369 392 371 359
    Gross Profit 505 485 463 427 470
    Total Operating Expense 717 695 687 621 654
    Selling/General/Admin. Expenses, Total 282 286 266 241 254
    Research & Development 33 34 23 33 43
    Other Operating Expenses, Total 2 6 6 -24 -2
    Operating Income 188 159 168 177 175
    Interest Income (Expense), Net Non-Operating -53 -29 -29 -6
    Net Income Before Taxes 135 130 106 149 169
    Net Income After Taxes 106 99 73 108 130
    Minority Interest 0 1 1 0 0
    Net Income Before Extra. Items 106 100 74 108 130
    Net Income 106 100 74 108 130
    Total Adjustments to Net Income 0 0
    Income Available to Common Excl. Extra. Items 106 100 74 108 130
    Income Available to Common Incl. Extra. Items 106 100 74 108 130
    Diluted Net Income 106 100 74 108 130
    Diluted Weighted Average Shares 135.395 135.395 135.395 135.395 135.395
    Diluted EPS Excluding Extraordinary Items 0.7829 0.73858 0.54655 0.79767 0.96016
    Dividends per Share - Common Stock Primary Issue 0 0 0.85 0 0
    Diluted Normalized EPS 0.7829 0.73858 0.54655 0.79767 0.96016
    Other, Net -62 1
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 1572 1406.6 1414.44 1150.22 850.576
    Cash and Short Term Investments 578 630.094 973.566 689.538 490.81
    Cash 689.538 490.81
    Total Receivables, Net 542 431.156 225.786 240.179 189.231
    Accounts Receivable - Trade, Net 454 391.4 216.494 233.321 181.002
    Total Inventory 405 312.894 204.027 208.82 161.186
    Prepaid Expenses 47 32.457 11.063 11.687 9.349
    Total Assets 20551 19428.8 2305.09 2138.69 1697.47
    Property/Plant/Equipment, Total - Net 318 332.974 142.113 173.359 94.126
    Property/Plant/Equipment, Total - Gross 763 670.152 331.608 346.227 238.758
    Accumulated Depreciation, Total -445 -337.178 -189.496 -172.87 -144.631
    Goodwill, Net 13874 12994.6 403.239 425.842 421.611
    Intangibles, Net 4648 4552.9 299.481 352.415 306.386
    Long Term Investments 36 49.224 39.46 32.674 23.602
    Other Long Term Assets, Total 103 92.473 6.354 4.173 1.166
    Total Current Liabilities 621 954.326 177.014 202.352 152.275
    Accounts Payable 181 173.081 25.922 29.314 32.085
    Accrued Expenses 134 206.528 77.454 86.23 64.526
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 182 455.673 13.593 14.632 0
    Other Current Liabilities, Total 124 119.044 60.045 72.176 55.664
    Total Liabilities 3815 4106.62 292.519 344.664 204.553
    Total Long Term Debt 2043 2026.82 48.81 61.213 0
    Long Term Debt 1988 1944.47 0
    Deferred Income Tax 1102 1068.7 16.211 27.273 29.329
    Minority Interest 4 18.695 4.444 3.605 3.298
    Other Liabilities, Total 45 38.083 46.04 50.221 19.651
    Total Equity 16736 15322.2 2012.57 1794.02 1492.91
    Common Stock 28 27.631 22.144 22.144 22.144
    Additional Paid-In Capital 13544 13544 494.61 494.61 494.61
    Retained Earnings (Accumulated Deficit) 3164 1750.57 1495.82 1277.27 976.16
    Total Liabilities & Shareholders’ Equity 20551 19428.8 2305.09 2138.69 1697.47
    Total Common Shares Outstanding 135.395 135.395 108.551 108.551 108.551
    Capital Lease Obligations 55 82.355 48.81 61.213
    Cash & Equivalents 578 630.094 973.566
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 1825 1816 1653 1572 1408
    Cash and Short Term Investments 778 687 618 578 461
    Cash & Equivalents 778 687 618 578 461
    Total Receivables, Net 535 612 573 542 492
    Accounts Receivable - Trade, Net 480 542 495 454 433
    Total Inventory 452 450 418 405 401
    Prepaid Expenses 60 68 45 47 53
    Other Current Assets, Total -1 -1 1
    Total Assets 21180 21648 20762 20551 20206
    Property/Plant/Equipment, Total - Net 353 349 307 318 342
    Goodwill, Net 14244 14552 14025 13874 13696
    Intangibles, Net 4573 4755 4629 4648 4635
    Long Term Investments 49 47 38 36 36
    Other Long Term Assets, Total 136 129 110 103 89
    Total Current Liabilities 596 651 596 621 670
    Accounts Payable 163 224 174 181 201
    Accrued Expenses 163 183 185 180 168
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 145 149 148 182 199
    Other Current Liabilities, Total 125 95 89 78 102
    Total Liabilities 3750 3971 3749 3815 3820
    Total Long Term Debt 2011 2125 2007 2043 2009
    Long Term Debt 1941 2050 1959 1988 1949
    Capital Lease Obligations 70 75 48 55 60
    Deferred Income Tax 1085 1132 1097 1102 1081
    Minority Interest 1 2 2 4 16
    Other Liabilities, Total 57 61 47 45 44
    Total Equity 17430 17677 17013 16736 16386
    Common Stock 28 28 28 28 28
    Additional Paid-In Capital 13544 13544 13544 13544 13544
    Retained Earnings (Accumulated Deficit) 3858 4105 3441 3164 2815
    Other Equity, Total -1
    Total Liabilities & Shareholders’ Equity 21180 21648 20762 20551 20206
    Total Common Shares Outstanding 135.447 135.447 135.447 135.395 135.395
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Oticon Fonden Corporation 28.6679 38829825 0 2023-06-30 LOW
    Bure Equity AB Private Equity 15.8809 21510257 0 2023-06-30 LOW
    Swedbank Robur Fonder AB Investment Advisor/Hedge Fund 4.3855 5940050 86430 2023-09-30 LOW
    Fjärde AP-Fonden Pension Fund 3.2713 4430886 -275000 2023-06-30 LOW
    AMF Tjänstepension AB Pension Fund 2.8867 3910000 1060000 2023-06-30 LOW
    Handelsbanken Kapitalförvaltning AB Investment Advisor/Hedge Fund 2.2083 2991013 -276773 2023-06-30 LOW
    SEB Investment Management AB Investment Advisor 1.8516 2507995 41154 2023-09-30 LOW
    GLG Partners LP Investment Advisor/Hedge Fund 1.6967 2298132 395717 2023-08-31 MED
    Cliens Asset Management AB Investment Advisor 1.6612 2250000 2250000 2023-06-30 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 1.4229 1927298 18953 2023-09-30 LOW
    Tredje AP Fonden Pension Fund 1.2863 1742207 1742207 2023-06-30 MED
    Morgan Stanley Investment Management Inc. (US) Investment Advisor/Hedge Fund 1.2177 1649280 -31380 2023-08-31 LOW
    Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 1.2164 1647539 1647539 2022-12-31 LOW
    Morgan Stanley Investment Management (Singapore) Investment Advisor/Hedge Fund 0.7981 1081033 -899948 2023-06-30 MED
    C WorldWide Asset Management Fondsmaeglerselskab A/S Investment Advisor 0.691 935938 -9466 2023-09-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 0.6816 923246 3176 2023-09-30 LOW
    Nordea Funds Oy Investment Advisor 0.6574 890402 2215 2023-09-30 LOW
    Comgest S.A. Investment Advisor 0.6235 844526 0 2023-06-30 LOW
    Lansförsäkringar Fondförvaltning AB Investment Advisor 0.5933 803542 837 2023-08-31 LOW
    Öhmans Asset Management Investment Advisor 0.4335 587109 0 2023-08-31 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Vitrolife Company profile

    About Vitrolife AB

    Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Vitrolife AB revenues increased 35% to SEK1.68B. Net income applicable to common stockholders increased 19% to SEK341M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Dividend per share remained flat at SEK0.80. Basic Earnings per Share excluding Extraordinary Items increased from SEK2.64 to SEK2.97.

    Equity composition

    1999: Stock Split in the ratio 1:2. 5/2018, 5-for-1 stock split (Factor: 5).

    Industry: Laboratory Diagnostic & Testing Substances

    Gustaf Werners gata 2
    Västra Frölunda
    GOETEBORG
    VASTRA GOTALANDS 421 32
    SE

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    XRP/USD

    0.63 Price
    -5.420% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Oil - Crude

    71.93 Price
    +0.620% 1D Chg, %
    Long position overnight fee -0.0204%
    Short position overnight fee -0.0015%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    Gold

    1,999.31 Price
    -0.260% 1D Chg, %
    Long position overnight fee -0.0199%
    Short position overnight fee 0.0117%
    Overnight fee time 22:00 (UTC)
    Spread 0.50

    US100

    16,049.90 Price
    -0.160% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading